Market cap
$27 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-70 Mln
-
ROE
-1.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.2
-
Debt to Equity
0.4
-
Book Value
$--
-
EPS
$-1.5
-
Face value
--
-
Shares outstanding
67,632,200
10 Years Aggregate
CFO
$-208.72 Mln
EBITDA
$-228.04 Mln
Net Profit
$-242.16 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Applied Genetic (AGTC)
| -79.3 | -1.6 | -4.2 | -82.5 | -48.4 | -36.5 | -- |
|
BSE Sensex*
| -9.3 | 2.0 | 0.1 | -5.7 | 6.6 | 8.0 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Applied Genetic (AGTC)
| -53.5 | -9.5 | 81.5 | -30.7 | -61.5 | -54.2 | -2.9 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Applied Genetic (AGTC)
|
0.4 | 26.6 | 0.3 | -70.2 | -21,080.9 | -217.2 | -- | 1.5 |
| 13.3 | 491.0 | 0.0 | -92.6 | -- | -47.5 | -- | 2.7 |
Shareholding Pattern
View DetailsAbout Applied Genetic (AGTC)
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology... development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida. Read more
-
Pres, CEO & Director
Ms. Susan B. Washer
-
Pres, CEO & Director
Ms. Susan B. Washer
-
Headquarters
Alachua, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Applied Genetic (AGTC)
What is the current share price of Applied Genetic (AGTC) Today?
The share price of Applied Genetic (AGTC) is $0.39 (NASDAQ) as of 09-Dec-2022 09:30 EDT. Applied Genetic (AGTC) has given a return of -48.43% in the last 3 years.
What is the current PB & PE ratio of Applied Genetic (AGTC)?
Since, TTM earnings of Applied Genetic (AGTC) is negative, P/E ratio is not available.
The P/B ratio of Applied Genetic (AGTC) is 1.51 times as on 09-Dec-2022, a 70 discount to its peers’ median range of 4.96 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.50
|
1.18
|
|
2021
|
-2.23
|
1.50
|
|
2020
|
-2.54
|
1.64
|
|
2019
|
-34.01
|
0.87
|
|
2018
|
-3.13
|
0.67
|
What is the 52 Week High and Low of Applied Genetic (AGTC)?
The 52-week high and low of Applied Genetic (AGTC) are Rs -- and Rs -- as of 21-Jun-2026.
What is the market cap of Applied Genetic (AGTC)?
Applied Genetic (AGTC) has a market capitalisation of $ 27 Mln as on 09-Dec-2022. As per SEBI classification, it is a Small Cap company.
Should I invest in Applied Genetic (AGTC)?
Before investing in Applied Genetic (AGTC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.